02:42 AM EDT, 08/12/2026 (MT Newswires) -- London-listed life sciences-focused investor RTW Biotech Opportunities (RTW.L) will invest a total of $5.9 million in Avere Therapeutics through two private placements. The private portfolio company, which accounts for 0.3% of RTW's net asset value as of June 30, will also implement a reverse merger with clinical-stage biopharmaceutical company NextCure, according to a Wednesday filing. The combined entity, expected to be created by the end of 2026 via an all-stock merger, will be named Avere Therapeutics and trade on Nasdaq under the ticker symbol AVRX. Both private placements are slated to close immediately before the completion of the all-stock merger. Avere will use the $820 million in proceeds to finance its lead asset AVR-001 through a phase 2b readout and phase 3 trial in psoriasis and a phase 2b trial in ulcerative colitis.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.